Full Press Release Details
CAMBRIDGE, England--(BUSINESS WIRE)--ScionxBio (the “company”, operating as a brand identity of Eleven Therapeutics Ltd. following a horizontal split) a privately held, preclinical-stage biotechnology company pioneering next-generation mRNA therapeutics, distinguished by their extended durability profile, today announced that it has entered into a worldwide strategic collaboration and licensing agreement with Sanofi (EURONEXT: SAN) (NASDAQ: SNY) to develop and commercialize extended exposure ver